{"id":353288,"date":"2016-04-04T10:46:59","date_gmt":"2016-04-04T15:46:59","guid":{"rendered":"https:\/\/content.findlaw-admin.com\/ability-law\/injury\/product-liability\/jentadueto-and-tradjenta-lawsuit-information.html"},"modified":"2025-09-03T10:00:15","modified_gmt":"2025-09-03T15:00:15","slug":"jentadueto-and-tradjenta-lawsuit-information","status":"publish","type":"page","link":"https:\/\/www.findlaw.com\/injury\/product-liability\/jentadueto-and-tradjenta-lawsuit-information.html","title":{"rendered":"Jentadueto and Tradjenta: Health Risks and Legal Information"},"content":{"rendered":"\n
\n

Jentadueto and Tradjenta: Health Risks and Legal Information<\/h1>\n\n
\n
\n By Natalie Moritz<\/a> | Legally reviewed by Jordan Walker, J.D.<\/a>\n | Last reviewed\n
\n \n <\/i>\n Legally Reviewed\n <\/summary>\n\n
\n

This article has been written and reviewed for legal accuracy, clarity, and style by FindLaw\u2019s team of legal writers and attorneys<\/a> and in accordance with our editorial standards<\/a>.<\/em><\/p>\n\n <\/div>\n <\/details>\n\n

\n \n <\/i>\n Fact-Checked\n <\/summary>\n\n
\n

The last updated date refers to the last time this article was reviewed by FindLaw or one of our contributing authors<\/a>. We make every effort to keep our articles updated. For information regarding a specific legal issue affecting you, please contact an attorney in your area<\/a>.<\/em><\/p>\n\n <\/div>\n <\/details>\n<\/section>\n\n\n

\n

Jentadueto and Tradjenta are type 2 diabetes drugs that help lower blood sugar by increasing insulin production and reducing glucose buildup. While effective, they have been linked to serious side effects like lactic acidosis, pancreatitis, and possibly pancreatic cancer.<\/p>\n\n <\/div>\n\n\n\n

Tradjenta is a type 2 diabetes medication used to regulate high blood sugar levels. A brand-name version of the generic drug linagliptin, Tradjenta is the product of an ongoing collaboration between Boehringer Ingelheim (BI) and Eli Lilly (EL), two of the largest pharmaceutical companies in the world. The\u00a0U.S. Food and Drug Administration (FDA) approved Tradjenta<\/a>\u00a0in 2011.<\/p>\n

Healthcare professionals often prescribe Tradjenta in conjunction with other diabetes medications. As a result, BI and EL manufactured a new drug called Jentadueto that combines Tradjenta (linagliptin) and metformin (a common type 2 diabetes medication). The FDA\u00a0approved Jentadueto in 2012<\/a>.<\/p>\n

Concerns have been raised regarding the suspected side effects of Tradjenta and Jentadueto. With possible links to serious complications, these drugs could subject their patients to significant harm. Manufacturers may be subject to government fines and\u00a0product liability lawsuits<\/a>.<\/p>\n

If you are concerned about taking Jentadueto and Tradjenta,\u00a0speak with your doctor. If you have suffered health problems after taking these drugs,\u00a0consider contacting a\u00a0product liability attorney<\/a>. An attorney near you can evaluate your claim and advise whether pursuing a lawsuit is worth your time and effort. If so, they will advocate for you throughout the legal process and seek fair compensation for your injuries.<\/p>\n

Treating Diabetes<\/h2>\n

Patients diagnosed with type 2 diabetes may receive a prescription for a type of medication called\u00a0incretin mimetics<\/a>. These drugs are designed to increase the body’s absorption of glucose and pancreas’s production of insulin. This dual-action drug treatment approach can help many patients lower their blood sugar levels.<\/p>\n

Some diabetes medications can also speed the pace of digestion, another contributing factor to diabetes.<\/p>\n

What are Jentadueto and Tradjenta?<\/h2>\n

Marketed by Eli Lilly and Boehringer Ingelheim, Jentadueto and Tradjenta are designed to lower blood sugar levels by reducing glucose buildup in diabetes patients. The U.S. Food and Drug Administration (FDA) approved\u00a0Tradjenta<\/a>\u00a0in May 2011 and\u00a0Jentadueto<\/a>\u00a0in January 2012.<\/p>\n

Jentadueto and Tradjenta are similar,\u00a0but not identical. Tradjenta’s active ingredient is linagliptin, which seeks to increase the pancreas’s production of insulin. Around the time Tradjenta reached the market, a series of studies endorsed treating diabetes patients with a combination of linagliptin and metformin, another diabetes drug.<\/p>\n

Jentadueto was designed to offer such a combination to patients in a single drug. Many medical sources treat Jentadueto and Tradjenta as essentially the same drug.<\/p>\n

Tradjenta and Jentadueto Help Regulate Blood Sugar Levels<\/h2>\n

Diabetics have difficulty producing insulin, a hormone that prevents sugar from building up in the bloodstream. Insulin is produced by the pancreas until the enzyme dipeptidyl peptidase-4 (DPP-4) causes the pancreas to stop production.<\/p>\n

Tradjenta and Jentadueto are part of a class of drugs known as\u00a0incretin mimetics\u00a0that mimic incretin, a hormone that\u00a0blocks the DPP-4 enzyme. By raising incretin levels, Tradjenta and Jentadueto are both DPP-4 inhibitors, allowing the pancreas to continue producing insulin. Ultimately, this results in lower blood sugar levels.<\/p>\n

Tradjenta and Jentadueto: Potential Serious Complications<\/h2>\n

While Tradjenta and Jentadueto are commonly prescribed to help manage type 2 diabetes, they are not without risks. Both medications have been associated with serious complications, including lactic acidosis, pancreatitis, and potentially pancreatic cancer.<\/p>\n

Understanding these risks is essential for patients to make informed decisions and respond quickly to changes in their health. Let’s take a look at each one.<\/p>\n

Increased Risk of Lactic Acidosis<\/strong><\/h3>\n

Packages of Jentadueto carry a\u00a0black box warning<\/a>, the FDA’s strongest type of warning. A black box warning indicates a potentially serious health risk or life-threatening complication.<\/p>\n

The black box warning for Jentadueto alerts consumers to the risk of lactic acidosis, which is attributed to the metformin used in Jentadueto. Lactic acidosis is the buildup\u00a0of lactic acid in the bloodstream<\/a>. It requires immediate medical attention and can sometimes be fatal.<\/p>\n

Some who use Jentadueto have an even higher risk of lactic acidosis. Patients at a higher risk include those:<\/p>\n